Clinical trials recruiting in Yonago, Japan
7
Recruiting trials
12
Conditions
Phase breakdown
Phase 1 2Phase 2 2Phase 3 5
Conditions recruiting in Yonago, Japan
Recruiting trials in Yonago, Japan
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Common questions
How many clinical trials are recruiting in Yonago, Japan?
7 recruiting trials have at least one study site in Yonago, Japan.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.